Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study-Reference-Cited by-同舟云学术

Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study

Published:2020-09-14 Issue:1 Volume:27 Page:70-77
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Zhang Li,Meng Li,Liu Bingcheng,Zhang Yanli,Zhu Huanling,Cui Jiuwei,Sun Aining,Hu Yu,Jin Jie,Jiang Hao,Zhang Xi,Li Yan,Liu Li,Zhang Wanggang,Liu Xiaoli,Gu Jian,Qiao Jianhui,Ouyang Guifang,Liu Xin,Luo Jianmin,Jiang Ming,Xie Xiaobao,Li Jianyong,Zhao Chunting,Zhang Mei,Yang Tonghua,Wang Jianxiang^ORCID

Funder

Hansoh pharmaceuticals

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic myeloid leukemia during osimertinib treatment in a non-small cell lung cancer patient: A case report;Heliyon;2024-09

2. Long-Term Remission in T315I+ Relapsed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Blinatumomab and Allogeneic Stem Cell Transplantation: Two Case Studies;American Journal of Case Reports;2024-07-02

3. Efficacy and safety of flumatinib in the treatment of newly diagnosed chronic myeloid leukemia in the chronic phase: A real-world single-center retrospective study, with a focus on premature drug discontinuation;Leukemia Research;2024-07

4. Overcoming flumatinib resistance in chronic myeloid leukaemia: Insights into cellular mechanisms and ivermectin's therapeutic potential;Journal of Cellular and Molecular Medicine;2024-07

5. Exploring treatment decision-making in chronic myeloid leukemia in chronic phase;Frontiers in Oncology;2024-07-01